| Skip to Content |
| Unit of Vitreoretinal Diseases |
| || || |
| || |
1. Combined treatment (photodynamic therapy and antiangiogenics) vs photodynamic therapy in patients with DMAE exudative: 1 year of results. Experimental Study. Estudio experimental.
It seeks to analyze the short to medium term retinal safety profile of the bevacizumab through intravenous injections in rats.
Clinical Trial. Objectives:
To study the effectiveness of the combined treatment of Photodynamic Therapy and intravenous Bebacizumab in patients with Age-related Macular Degeneration.
To study the effectiveness of the combined treatment of Photodynamic Therapy and intravenous Ranivizumab in patients with Age-related Macular Degeneration.
To study the evolutional behaviour during the first year of the neovascular membranes in said patients.
Pretende analizar el perfil de seguridad retiniano del bevacizumab a corto y medio plazo, mediante su inyección intravítrea en ratas.
The objective is to compare the results obtained with the results of the patients treated with only Photodynamic Therapy.
2. Wide field angiography
Comparison of the conventional digital angiography system for classification and the treatment of the diabetic retinopathy.
This line seeks to study the consistency of the ocular fundus images and of angiography obtained through the wide field angiograph Optomap versus the images obtained through the conventional angiograph Topcon Imagenet in patients with diabetic retinopathy.
Once completed, it will proceed to evaluate the degree of confidence of two different observers of the images obtained through the two angiographic techniques described in the same case.
3. Safety in the peeling of the macular membranes tinted with high doses of bright Blue G.
The aim is to determine if the high doses of Bright Blue G (1mg/ml) in 5% glucose can simplify the macular surgery (epiretinal membranes and limited internal peeling in macular holes) without toxic effects.
4. Combined treatment for the myopic neovascular membranes (MNV): photodynamic therapy (tfd) + bevacizumab.
This study will evaluate if the combined and personal treatment (TDF+Bevacizumab) in the myopic MNV can improve vision, and if it is possible to reduce the frequency of intravenous injections of the anti-angiogenics.
Follow-up at 1 year.
| || || |